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Background: Alzheimer’s disease (AD) is the leading cause of dementia affecting greater than 26 million people
worldwide. Although cerebrospinal fluid (CSF) levels of Aβ42, tau, and p-tau181 are well established as diagnostic
biomarkers of AD, there is a need for additional CSF biomarkers of neuronal function that continue to change
during disease progression and could be used as pharmacodynamic measures in clinical trials. Multiple proteomic
discovery experiments have reported a range of CSF biomarkers that differ between AD and control subjects. These
potential biomarkers represent multiple aspects of the disease pathology. The performance of these markers has
not been compared with each other, and their performance has not been evaluated longitudinally.
Results: We developed a targeted-proteomic, multiple reaction monitoring (MRM) assay for the absolute quantitation
of 39 peptides corresponding to 30 proteins. We evaluated the candidate biomarkers in longitudinal CSF samples
collected from aged, cognitively-normal control (n = 10), MCI (n = 5), and AD (n = 45) individuals (age > 60 years). We
evaluated each biomarker for diagnostic sensitivity, longitudinal consistency, and compared with CSF Aβ42, tau, and
p-tau181. Four of 28 quantifiable CSF proteins were significantly different between aged, cognitively-normal controls
and AD subjects including chitinase-3-like protein 1, reproducing published results. Four CSF markers demonstrated
significant longitudinal change in AD: Amyloid precursor protein, Neuronal pentraxin receptor, NrCAM and Chromogranin
A. Robust correlations were observed within some subgroups of proteins including the potential disease progression
markers.
Conclusion: Using a targeted proteomics approach, we confirmed previous findings for a subset of markers, defined
longitudinal performance of our panel of markers, and established a flexible proteomics method for robust multiplexed
analyses.
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Multiple-reaction monitoringBackground
Alzheimer’s disease (AD) is the most common form of
dementia and the 6th leading cause of death in America
[1]. The pathological hallmarks of AD are extracellular
plaques composed of amyloid beta (Aβ) and neurofibrillary
tangles composed of hyperphosphorylated tau (p-tau).
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unless otherwise stated.of CSF tau and p-tau181 are observed in AD patients in
comparison with aged, cognitively-normal individuals, and
these changes in CSF correlate with the pathological
hallmarks of AD [2,3]. The change in levels of Aβ42 and
tau begin 1–2 decades prior to onset of symptoms, with
the change in Aβ42 preceding that of tau [4,5].
CSF Aβ42, tau and p-tau181 are routinely used in AD
research and drug development. However, while the
rank order performance (relative quantitation) of these
biomarkers has been consistent, the inter-laboratory
variability in the absolute value has been high [6-8]. Inral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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overlap between levels in controls and AD patients.
Further, none of the three established CSF biomarkers
have been directly linked to efficacy in a clinical trial.
For example, while CSF levels of tau and p-tau181
levels did trend toward decline after treatment with
bapineuzumab, no correlation with cognitive benefit
was observed (reviewed in [9]).
There is a need to develop additional biomarkers
that can aid in the diagnosis and treatment of AD. Many
proteomic studies have identified potential AD biomarkers
(reviewed by [10,11]), generating a substantial list of
candidates that need to be evaluated for their utility.
However, follow-up studies focusing on individual
candidates are limited and usually focused on markers
for which existing immunoassays are available. The
development time for a new immunoassay can be
significant and relies on successful identification of specific
and high affinity antibodies. Targeted-proteomics is an
emerging tool to accelerate hypothesis driven biomarker
assay development by enabling the quantitative assessment
of potentially hundreds of biomarkers simultaneously
(reviewed in [12-14]).
Candidate AD biomarkers in CSF were selected based
upon the consistency of their identification in proteomic
discovery experiments [15-23]. These experiments used
many different proteomic approaches, including differences
in sample preparation (in-gel vs. in-solution digestion), the
mass spectrometer (MS) used for analysis (MALD-ToF vs.
FT-ICR), and the quantitation technique (label-free vs.
iTRAQ). The differences in the proteomic techniques may
account for some discrepancies in the trend of change
observed for certain markers, but more importantly
highlight the need for targeted-follow-up of candidate
biomarkers within a single sample set. Independent of the
proteomic experiments, additional candidate biomarkers
were selected for evaluation based on their known
relationship with AD (e.g. apolipoprotein E4) [24], or
their emerging promise as disease progression markers
(ex. Visinin-like-protein 1) [25,26].
A multiplexed, absolute quantitative LC-MS/MS multiple
reaction monitoring (MRM) assay was developed to quanti-
tate candidate biomarker-specific peptides in CSF samples
from cognitively-normal, aged control, mildly-cognitively
impaired (MCI) and AD patients. We evaluated the diag-
nostic utility of all the protein-specific peptides in compari-
son with the published proteomic literature and also
compared with the classic AD CSF biomarkers Aβ42, tau
and p-tau. The longitudinal performance of each biomarker
(sampled serially from the same patient) was established,
with the majority of peptides demonstrating stability over
the course of a year. Four candidates decreased over time
in AD patients. Results from this targeted-proteomic assay
narrow the list of candidates for more rigorous follow-upand increase the rate of development of novel clinical
biomarkers for AD.
Results
CSF biomarker MRM panel development
Based on a review of the CSF discovery proteomics and
biomarker literature, initially 50 candidate biomarkers
were selected for evaluation. Of these, 30 proteins were
detectable in pooled cynomolgus monkey and pooled
human CSF (from young-cognitively normal control and
Alzheimer’s subjects) by a high resolution LTQ-orbitrap
MS operating in unbiased, discovery mode (Table 1).
Representative peptides for each biomarker candidate were
selected based upon the robustness of their detection in
CSF. For example, the quantitation of 41 peptides
was compared in three AD CSF samples after one or
two freeze thaws. The freeze thaw performance was
of special importance for this experiment because of
different collection protocols used for the AD CSF
samples; some of the AD samples underwent one more
freeze-thaw cycle than the other samples analyzed in this
study. The 39 peptides selected in the final MRM panel in-
clude peptides from the 30 detectable proteins as well as
peptides from blood contamination markers, a non-
endogenous internal standard, and one CSF protein which
was undetectable in the discovery experiment. The peptides
are listed in Additional file 1: Table S1; they demonstrated
no difference in peptide performance between 1 vs. 2
freeze-thaw cycles (Additional file 2: Figure S1, Pearson r =
0.9938). Peptides with intra-assay and inter-assay CVs of
less than 20% were analyzed in patient samples (a summary
of peptide performance is shown in Additional file 1:
Table S1. LODs, LOQs and % CV was determined from the
performance of 4 different calibration curves prepared on
different days run in duplicate or triplicate). For the major-
ity of proteins only one signature peptide was selected, with
a few exceptions for lower abundance proteins or proteins
for which specific peptides (i.e. isoform-specific) were previ-
ously published or known to have significance to disease
(i.e. APOE4). When possible, species conserved peptides
were selected (ex. cynomolgus monkey to human). Peptides
were quantitated using the AQUA approach [27,28]; briefly,
stable-isotope peptides for each candidate-peptide were
synthesized and used as internal standards. The ratio of the
light (endogenous) to heavy (stable-isotope-labeled) peptide
was mapped to an external calibration curve of known
ratios of pure light to heavy peptides. In addition, a non-
endogenous protein (horse myoglobin) was spiked into
CSF at the beginning of the sample preparation to serve as
a quality control measure for sample processing [29].
Diagnostic evaluation
Thirty-nine peptides (Additional file 1: Table S1) were
quantitated in baseline CSF tryptic-digests from 10 aged
Table 1 Selected CSF AD biomarker candidates
Uniprot ID Identifier Protein Link to AD Change in AD
P01009 A1AT α-1-antitrypsin Neuroinflammation [16-18,30-33]
P04217 A1BG α-1-beta-glycoprotein Unknown [17,20,34]
P02768 ALBU Albumin Aβ polymerization [17,18]
P05067 A4 Amyloid precursor protein Aβ peptide precursor [35]
P51693 APLP1 Amyloid precursor-like protein 1 Beta and gamma secretase substrate [36]
P02649 APOE Apolipoprotein E Apolipoprotein, Aβ clearance [15,17,18,20,33,37]
Q8TCZ8 APOE4 Apolipoprotein E4 Apolipoprotein, risk factor for AD [22]
P02749 APOH Apolipoprotein H (beta-2-glycoprotein 1) Apolipoprotein [15,20,21]
P61769 B2MG Beta-2-microglobulin Aβ-binding molecule [15,17,19,20,22,37-41]
P00450 CERU Ceruloplasmin Antioxidant [34,42,43]
P36222 CH3L1 Chitinase-3-like protein 1 (YKL-40) Neuroinflammation [15,20,22,23,44]
P10645 CMGA Chromogranin A Neurodegeneration [15,19,20,22,41,45-47]
P10909 CLUS Clusterin (ApoJ) Apolipoprotein, Aβ clearance [15-18,22,33,47]
Q12860 CNTN1 Contactin 1 Neurodegeneration [16,18]
Q02246 CNTN2 Contactin 2 Neurodegeneration [16,18]
P01024 CO3 Complement component C3 Neuroinflammation [18,45,48,49]
P0C0L4 CO4 Complement component C4 Neuroinflammation [16,22,34,49]
P01034 CYTC Cystatin C Aβ-binding molecule [15,19,20,22,32,38,41,47]
O95502 NPTXR Neuronal pentraxin receptor Neurodegeneration [15,18,50]
Q92823 NRCAM NrCAM Neurodegeneration [22,45,51]
P00747 PLMN Plasminogen Aβ clearance [18]
P04156 PRIO Prion protein β Secretase BACE1 inhibitor [39,40,52]
P41222 PTGDS Prostaglandin-d2 synthase Aβ binding protein [16,20]
P02753 RET4 Retinol binding protein Unknown [15,17,18,37,39,40,53,54]
P08294 SODE Superoxide dismutase Target of oxidative damage in AD [15,34]
P05452 TETN Tetranectin Neurodegeneration [15,16]
P02787 TFRE (sero)transferrin Oxidative damage in AD [15,17,34,39,40]
P02766 TTHY Transthyretin Aβ-binding molecule [15,17,18,22,37,39,40,54-57]
P62760 VISL1 Visinin-like protein 1 Neurodegeneration [25,26,58]
P02774 VTDB Vitamin D Binding protein Aβ-binding molecule [15,18,39,40]
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subjects. The CSF sample demographics are summarized
in Table 2. Mini-mental state exam (MMSE) cognitive
scores were significantly different between control and







n 10 5 45
Sex, M/F 7/3 2/3 30/15
Age, median 68.5 76 77.5
Age, mean (range) 68.8 (64–75) 74 (66–80) 76.9 (61–90)
MMSE score, median 30 24 20
MMSE score, mean (range) 29.4 (25–30) 23.4 (21–26) 19.7 (6–27)were consistent with the clinical diagnosis provided by
the vendor (Table 2). Similarly, the trends observed for
the classic CSF biomarkers Aβ42, total tau, p-tau181 were
consistent with diagnosis (Figure 1A-C). There was a
significant difference between the mean age of the groups
(control vs. AD p < 0.005, control vs. MCI p < 0.05), so it
was important to include as a covariate in our analyses.
Four peptides were significantly different between control
and AD subjects (linear regression of log values adjusted
for age and sex, p < 0.05, corrected by the Benjamini &
Hochberg method) (Table 3, Additional file 3: Figure S2).
Only Chitinase-3-like protein 1 (CH3L1 aka YKL-40) was
at or above the significance level of the common diagnostic
biomarkers Aβ42, total tau, p-tau181 and the MMSE cogni-
tive scores. CH3L1 increased in AD by 1.6-fold (Figure 1D),
which is similar to the degree of change observed for
Figure 1 Difference in Chitinase-3-like protein 1 (CH3L1 aka YKL-40) is comparable with the change observed for Aβ42, tau and p-tau181 in
AD vs. aged cognitively-normal controls (age > 60y) (linear regression, **p = 0.001-0.01, ***p < 0.001). Control, green-circle, MCI blue-square,
AD red-triangle. A. CH3L1, B. Aβ42, C. total tau, D. p-tau181.
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appears to change in MCI vs. control and 2 biomarkers,
PTDGS and APOE_301 reached significance in AD vs.
MCI (Table 3, Additional file 3: Figure S2), but due to the
low subject number (MCI, n = 5), analysis of a greater
number of subjects should be pursued to assess diagnostic
potential.Table 3 Summary of biomarkers that differ at baseline betwe
G
AD/Ctl




Total Tau 0.004 2.0






p values represent linear regression comparison of log values (corrected by the Ben
all measurements with p < 0.05. Fold difference reflects ratio of the average baselin
measurements of Aβ42, total tau and p-tau are included for reference (italicized). (ALongitudinal performance
It is estimated that levels of Aβ42 and tau change 1–2
decades prior to AD onset [4,5]. However, both markers
demonstrate limited to no annual change in established
AD patients [59-63]. One of the primary goals of our
study was to evaluate the longitudinal stability of the
candidate biomarkers. We estimated the annualizeden diagnostic groups
roup comparison
MCI/Ctl AD/MCI




jamini & Hochberg method), adjusting for age and sex, and the table includes
e measurements between groups. Differences for MMSE and ELISA
D n = 45, Ctl n = 10, MCI n = 5, aged >60y).
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three time points collected repeatedly from the same
patients (baseline, 3–8 mo., 11–16 mo.) including age and
sex as covariates [64]. As expected, both Aβ42 and tau
remained stable in the AD subjects’ samples analyzed in
this study (Figure 2) (% annual change for Aβ42 = −0.1%,
95% CI = −7.3 - 7.7% annual change for tau = −5.4, 95%
CI = −16.1-6.6). P-tau trended toward a decrease in AD,
but the change from baseline did not reach significance
(% annual change for p-tau = −10.8%, 95% CI = −21.4-1.3).
The annual rate of yearly change was estimated for all
peptides in AD subjects (Figure 3). The majority of
peptides were stable over time, however, four peptides
demonstrated significant decreases over time in AD
as indicated by the 95% confidence interval error bars
(~10% per year) (amyloid precursor protein, A4_117;
neuronal pentraxin receptor, NPTXR; Chromogranin
A, CMGA; and NrCAM) (Figure 3). The individual
trajectories and the mean group slope are shown in
Figure 4 for the four potential longitudinal biomarkers.
There was no significant change from baseline observed in
a smaller set of aged control and MCI patients (Figure 4).
Correlation analysis
The relationship of all peptides with each other as well
as with Aβ42, tau and p-tau181 was compared. Spearman
rank correlations were assessed in all samples, and the most
significant correlations (|r > 0.8|) are shown in Table 4.
Chromogranin A (CMGA), NrCAM and Neuronal pentra-
xin receptor (NPTXR) were the most highly correlated
biomarkers (Figure 5) with correlation coefficients greater
than 0.9 for all subjects independent of group, sex, age or
time point. When measured by ELISA, CMGA and
NrCAM were also highly correlated, and the rank
order was consistent with the MRM result (Figure 5D,
R = 0.93); thus confirming the observed correlation by an
independent method. In addition, within AD patients
(baseline) these three tightly correlated peptides did not
correlate with levels of CSF total protein (n = 32) or Aβ42
(n = 21) (Additional file 1: Table S2), however they did
correlate with tau (n = 21)(CMGA R = 0.69, NPTXR
R = 0.71, NrCAM R= 0.74) (Additional file 1: Table S2).
Discussion
Using a multiplexed, targeted-proteomics approach we
evaluated candidate biomarkers for AD that were previously
reported in discovery proteomic experiments to change
with disease. At least one surrogate peptide was selected for
each protein, and 4 specific transitions were selected for
each peptide. Stable-isotope labeled peptides (heavy) were
used as internal standards for every endogenous peptide
(light), and the ratio of the peptide pair (light to heavy)
was used for absolute quantitation. Using CH3L1 as
an example (Figure 1D), absolute quantitation by thisapproach yields results similar to that of traditional
immunoassays [22,23,44,65].
One of the major benefits of our approach, especially
when working in a less-complex matrix like CSF, is that
sample preparation does not require sample enrichment
approaches. For example, sample enrichment using
antibodies, even in the case of depleting the most
abundant proteins, such as albumin, can add bias due
to co-depletion of proteins of interest [66]. However,
enrichment strategies are usually needed when additional
sensitivity is required. In this assay, the concentration
range in CSF for the 28 proteins detected was 28 ng/mL
to 13.8 μg/mL, which is consistent with the expected
dynamic range of current instruments. Visinin like protein
1 (VILIP-1) was below the level of detection for all three
peptides that were monitored; targeted-enrichment
strategies or development of a sensitive immunoassay
will be required to evaluate this candidate biomarker.
While not a primary focus of our study due to our small
group sizes, we did evaluate the diagnostic performance of
all the candidate biomarkers in comparison with the classic
AD CSF biomarkers. The directionality and fold-difference
observed between diagnostic groups was as expected for
Aβ42, tau and p-tau in our sample set (Figure 1, Table 3);
this result gave us confidence that these samples are
representative of their respective diagnostic groups and
that they could be used to evaluate the performance of
the candidate biomarkers. After correction for multiple
comparisons testing, a number of peptides reached signifi-
cance in differentiating the diagnostic groups (Table 3).
However, due to the small group size, replication with
more individuals needs to be performed, especially for
the MCI group comparisons. The observed modest
differences between groups (0.6-2 fold-differences) are
comparable with what others have reported; proteomic
studies of larger sample sets have demonstrated that the
majority of candidates change by less than 2-fold in AD
[16,22]. Extending from sporadic AD to familial AD,
Ringman et al. also reported that complement component
C3 (CO3) increased in disease by 1.3 [34], in comparison
with our observed changes of 1.4. Also consistent with
previous reports, the traditionally used biomarkers Aβ42,
tau and p-tau181 were the most significant and specific
markers differentiating AD patients from control. The
other significant biomarkers detected lack specificity;
they have also been reported to change in other neurode-
generative diseases including Parkinson’s disease and
multiple sclerosis [15,16,67]. The biomarkers evaluated in
this study may have greater utility for disease-staging
rather than diagnostics [22] or for monitoring therapeutic
response, especially if used in combination; if multiple
molecules from the same pathway change in response
to treatment, it would give one higher confidence of a
therapeutic effect.
Figure 2 Classical CSF biomarkers of AD are stable in established disease. Black-line mean slope. Control, green-circle, MCI blue-square, AD
red-triangle. Closed symbols, decliners. A. Aβ42, B. total tau, C. p-tau181.
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Figure 3 Estimated annual change of biomarkers in AD patients (n = 45) adjusted for age and sex. Dot, mean change. Line, 95%
confidence interval.
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of a candidate biomarker prior to use in the clinic.
Multiple studies have demonstrated that CSF Aβ42
levels stabilize and plateau in established AD [59-63].
Similarly CSF tau and p-tau appear to demonstrate
longitudinal stability [68], though some studies have
noted a slight continued longitudinal increase in tau
[60,63]. In our longitudinal assessment of the classic
AD biomarkers, Aβ42 and tau levels were stable over
the course of a year in our AD patients (Figure 2),
consistent with previous reports. Similar to Aβ42 and
tau, the majority of peptides were stable over time
(11–16 months) in AD patients (Figure 3). There were
four peptides (A4_117, CMGA_322, NPTXR_22, andFigure 4 Potential longitudinal biomarkers in established AD patients
red-triangle. Closed symbols, decliners. A. Amyloid precursor protein peptid
A (CMGA), D. NrCAM.NRCAM_806) that declined significantly by approximately
10% per year in the AD patients but not in aged control or
MCI patients (Figure 4). P-tau trended toward decline over
time in 14 of 24 patients (Figure 2). A decline in p-tau
(2 pg/mL/year) has been observed previously in sporadic
AD patients [69], and more recently in autosomal-
dominant AD patients [70]. Fagan et al. also showed that
levels of VILIP-1 decreased after the onset of disease [70],
suggesting that at later stages of disease a decline in CSF
biomarkers, like VILIP-1, are reflective of neuronal
loss. The four markers identified in this study are also
neuronal markers, and are potential progression markers
in Alzheimer’s patients that will be further evaluated in
additional longitudinal sample sets.. Black-line mean slope. Control, green-circle, MCI blue-square, AD
e (A4_117), B. Neuronal pentraxin receptor (NPTXR), C. Chromogranin
Table 4 Most significant correlations for all time points
and all groups (Spearman) (R > 0.8)
Peptide X vs. Peptide Y R (Spearman rank)
CMGA_322 vs. NRCAM_806 0.93
CMGA_322 vs. NPTXR_22 0.93
NPTXR_22 vs. NRCAM_806 0.92
APOE_301 vs. B2MG_69 0.88
CYTC_36 vs. TETN_51 0.88
B2MG_69 vs. TETN_51 0.88
A4_688 vs. NRCAM_806 0.87
B2MG_69 vs. PRIO_195 0.87
CLUS_183 vs. PTDGS_23 0.87
A4_688 vs. CMGA_322 0.87
A4_688 vs. NPTXR_22 0.85
PRIO_195 vs. TETN_51 0.83
APOE_301 vs. PRIO_195 0.83
CERU_70 vs. CO3_1172 0.82
CERU_70 vs. PLMN_681 0.81
APOE_199 vs. APOE_301 0.80
Figure 5 Chromogranin A (CMGA), NrCAM, and Neuronal pentraxin re
concentrations are also correlated by ELISA (D) (Baseline for all group
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NrCAM and NPTXR were also highly correlated (Figure 5).
The fourth candidate progression marker amyloid precur-
sor protein (APP) peptide A4_117 was also correlated
with the three other peptides, however, the Spearman
rank correlation coefficient was below our |R > 0.8|
cut-off (A4_117 correlations: NrCAM R = 0.65, CMGA
R= 0.62, NPTXR R= 0.6). Another APP peptide quanti-
tated in this study, A4_688, did not demonstrate significant
longitudinal change. The lack of strong correlation between
the two APP peptides, A4_117 and A4_688 (Spearman
rank R = 0.42), may be a consequence of differential CSF
kinetics of APP cleavage fragments (Figure 6). Based on the
full-length sequence of APP A4770, A4_117 corresponds to
amino acids (a.a.) 117–132, which is present in soluble APP
(sAPP) α (a.a.18-687) and sAPPβ (a.a.18-671) as well
as N-APP (a.a.18-286). In contrast, A4_688 corresponds
to a.a. 688–699 from full-length APP as well as a.a. 17–28
within Aβ [71]. The differential behavior of these peptides
demonstrates the importance of distinguishing peptide-
level quantitation from total protein quantitation, and
caution against algorithms that automatically combine
peptide quantitation into a single protein quantitation.
The correlations were remarkably high for some of
these biomarkers and possible analytical factors wereceptor (NPTXR) are highly correlated (A-C), NrCAM and CMGA
s, Control, green-circle, MCI blue-square, AD red-triangle).
Figure 6 Peptides from different regions of Amyloid Precursor Protein (APP, A4) reflect different processing products.
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were ruled out; for example, peptide properties including
retention time and m/z were different in each case. To
support the hypothesis that the correlations are not an
artifact of the detection method, NrCAM and CMGA
levels were analyzed using ELISAs. A similar rank order
was observed in the MS assay and ELISA (Figure 5D).
Interestingly, the absolute levels measured by the NrCAM
ELISA were significantly lower than that measured by
the MS assay. The difference in absolute value be-
tween the NrCAM ELISA and MS result may be due
to the fact that NrCAM exists as multiple isoforms in
CSF. The antibody used in the ELISA may not detect
all the isoforms; however, the peptide used for the
MS assay is present in all 5 NrCAM isoforms, which
would account for the higher value observed by MS. Al-
though the absolute values were different from the two
methods used, the fact that the rank orders are maintained
support the hypothesis that the high correlation for some
biomarkers reflects a common biological process. CMGA,
NPTXR, NrCAM, and A4_117 and A4_688 are all pro-
duced in neurons, and changes in these peptides may
be reflective of neurodegeneration. NrCAM is an ad-
hesion molecule present on synapses [45,72]. CMGA
is a prohormone that is packaged in dense-core syn-
aptic vesicles [46,73,74]. NPTXR and APP are both
integral-membrane proteins. NPTXR has been implicated
in synaptic plasticity [75,76], and APP is known to be
critical to synapse formation and function [77]. Given
the diverse biological roles of these proteins, the observed
correlations suggest that coordinated changes in CSF may
reflect pathologies beyond Aβ and tau (e.g. synaptic func-
tion or secretion mechanisms). Interestingly, CMGA,
NPTXR, and NrCAM are also positively correlated with
tau within our AD samples (R = 0.69, 0.71, 0.74, respect-
ively, Additional file 1: Table S2), although not as strongly
as they are correlated with each other. VILIP-1, a potentialmarker of neurodegeneration, is also positively correlated
with tau [26]. Future studies are needed to increase
our understanding of the underlying cause of these
correlations, the spectrum of other CSF proteins that are
correlated with this initial cluster, and the longitudinal
performance and utility of the correlations.
Conclusions
It is now clear that Alzheimer’s disease pathology begins
years before the onset of clinical symptoms, and therapeutic
trials are beginning to focus on treating patients prior to
the onset of dementia. Thus, the need for biomarkers that
can increase the accuracy of early diagnosis and reflect
the success of treatment is critical for AD researchers,
clinicians, and patients. Ideally, biomarkers will be discov-
ered that reflect multiple processes such as neuroinflam-
mation, neuronal stress and neuronal dysfunction, which
will enable intervention prior to significant neuronal
loss. In addition, biomarkers are needed to monitor
progression of disease in established patients. To
accelerate the assessment of candidate biomarkers, we
developed an absolute quantitative assay for 30 candi-
date protein biomarkers (Table 1). Biomarkers that
were significantly different between diagnostic groups
at baseline (fold differences ranging from 0.6-1.6)
(Table 3), reproduced published discovery proteomic
results. Four of the markers emerged as potential progres-
sion markers in AD (Figure 4). Multiplexing enabled the
exploration of relationships between CSF biomarkers; we
discovered highly correlated proteins that may serve
as markers of neurodegeneration in established AD
patients (Figure 5). Multiplexed, targeted-proteomics
proved to be a robust approach with relatively rapid
assay development time enabling the assessment and
prioritization of biomarker discovery candidates. This
approach promises to fill a much needed gap in clinical
biomarker development.
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Source of CSF
CSF was purchased from Bioreclamation, LLC (Hicksville,
NY) (pooled cynomolgus monkey and pooled human
CSF used in discovery experiments), Folio Biosciences
(Columbus, OH) (individual longitudinal AD only)
and PrecisionMed, Inc. (San Diego, CA) (individual
longitudinal Control, MCI and AD). Details on sample
collection were provided by the vendors. All donors
provided informed consent for use of these studies with
institutional review board approval for human collection
protocols. CSF was collected in the morning under fasting
condition. Lumbar punctures were performed at L3-L4 or
L4-5 using a sprotte needle (5 mL), and the CSF was cen-
trifuged and then immediately aliquoted in polypropylene
tubes and snap frozen at −80°C. Bloody taps or visually
“pink” CSF were excluded. AD or MCI subjects had MMSE
between 14 and 28, were greater than 60 years old,
Hachinski score ≤4, diagnosed with dementia or MCI
established by a clinical examination and documented
by MMSE and other neuropsychological tests. Aged
cognitively-normal individuals were 64–75 years old,
healthy, exhibited normal memory function documented
by results within the normal range for CDR word recogni-
tion test, and had an MMSE score of greater than 28. The
diseased population samples from PrecisionMed were
thawed at the vendor for aliquoting, and thus underwent
one more freeze-thaw cycle than the other samples
analyzed in this study.Total protein measurements
Concentrations of CSF total protein were provided by
Folio Biosciences as part of the clinical data for each AD
subject.Immunoassay measurements of CSF Aβ1–42, Tau, and
p-Tau181
INNO-BIA AlzBio3 Kit (Innogenetics®, RUO) was used
according to the manufacturer’s protocol. Briefly, beads
conjugated to monoclonal antibodies against Aβ1–42
(4D7A3), Tau (AT120), or p-Tau181 (AT270) were mixed
with biotinylated monoclonal antibodies against the same
targets (3D6 for Aβ1-42, HT7 for Tau and p-Tau181).
75 μL of undiluted CSF was incubated overnight at room
temperature with mild agitation. The beads were then
washed, and a solution of streptavidin-PE was added to
the beads for 1 h to enable detection of bound analytes.
After an additional wash, a read solution was added to the
beads and they were then analyzed with the Bioplex
200 system (Biorad, Hercules, CA). Only a subset of
the AD samples (25 of 45), representative of both
vendors, were assayed due to a limited availability of CSF
for some subjects.CSF tryptic digestion and peptide quantitation
400 μL of CSF was spiked with 100 ng of equine myoglobin
(Sigma, St. Louis, MO) and concentrated to 30 μL in a
3 kDa Amicon centrifugal concentrator (Millipore, Billerica,
MA). Samples were denatured in 40% trifluoroethanol
(TFE) (Sigma) prepared in 100 mM triethylammonium
bicarbonate (TEABC) (Sigma) (1 h 37°C). Samples were
reduced with 5 mM dithiothreitol (DTT) (30 min RT),
alkylated with 20 mM iodoacetamide (IAM) (30 min, RT in
the dark), and quenched with an additional 5 mM DTT
(15 min, RT). Samples were diluted to 10% TFE with
100 mM TEABC, and then digested with trypsin (1:25,
18 h, 37°C). The digestion was stopped by the addition of
formic acid. The final volume of all digests was measured.
An aliquot of the total digest (48 uL) was spiked with
a mixture of stable-isotope-labeled AQUA peptides (2 uL)
(Cell Signaling Technologies, Danvers, MA) prior to
LC-MS/MS analysis. Protein-AQUA™ peptides were
synthesized by Cell Signaling Technologies and purified
by reversed-phase HPLC, and analyzed by MALDI-TOF
MS and nanospray tandem MS. An accurate peptide
concentration was measured by amino acid analysis, and
provide by the vendor. Heavy AQUA peptides to be spiked
into samples were diluted and pooled before use to
concentrations that were within 10-fold of endogenous
protein levels and ranged from 2–100 fmol/uL depending
on analyte. In addition, a pool of heavy (stable-isotope
labeled) and light (unlabeled) AQUA peptides was
prepared and diluted serially to generate calibration
curves. The heavy peptide mixture was prepared first. The
light peptide was diluted serially using the heavy peptide
mixture to hold the concentration of the heavy peptide
constant (at the same concentration used for the internal
standard spike). Heavy and light peptides used for calibra-
tion curves were prepared and qualified in an artificial
CSF matrix (bovine serum albumin digest) to select 4
transitions for MRM, establish limits of detection (LOD)
and limits of quantitation (LOQ). The observed fmol
on-column (2 uL of digest) was converted to nM
using a volume correction factor to express the result
in relation to the original sample volume. The ranges in
human CSF samples and biologic functional roles are
summarized in Additional file 1: Table S1 for peptides that
demonstrated consistent performance (<20% CV). Values
represent the median of 4 different calibration curves
prepared on different days run in duplicate or triplicate.
Discovery LC-MS/MS analysis
Digested proteins from pooled CSF (cynomolgus
monkey, human young normal and Alzheimer’s disease
subjects) were analyzed by capillary reverse phase liquid
chromatography-electrospray ionization tandem mass
spectrometry. Aliquots (5 μL of 25 total) were loaded onto
the trapping column (BEH C18; 180 μM i.d. × 20 mm with
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ultra high pressure liquid chromatography system
and eluted through a resolving column (BEH C18;
100 μm i.d. × 100 mm, 1.7 μm particles) at a flow
rate of 1 μL per minute using a linear gradient from
2 to 30% solvent B over 35 minutes followed by a
ramp to 50% B in 3 minutes and a step and hold at
90% B for 5 minutes, returning to 2% B for a 7 minute
re-equilibration. Solvent A was 0.1% formic acid in
water and solvent B was 0.1% formic acid in acetonitrile.
Eluted peptides were directed to the electrospray source
(CaptiveSpray; Michrom Bioresources, Inc., Auburn, CA)
of an LTQ-orbitrap mass spectrometer (Thermo Scientific,
Waltham, MA) operated in a “top-8” data-dependent
mode whereby high resolution scans of peptide masses in
the orbitrap analyzer were followed by ion trap collision-
induced dissociation of the 8 most abundant multiply
charged ions. Tandem mass spectra were searched against
the “UniProt” database of human proteins using the
Mascot program (Matrix Science Ltd.) using a “semi-tryptic”
enzyme specificity and 25 ppm precursor ion tolerance,
with cysteine carbamidomethylation as a static modification
and allowing for oxidized methionine as a variable
modification. Database hits were filtered to a false discov-
ery rate of less than one percent using a “target-decoy”
linear discriminant procedure.
Targeted LC-MRM analysis
Samples (2 μL) were loaded onto a nanoAcquity UPLC
(Waters, Milford, MA), desalted on a Symmetry® C18 trap
column (180 μm × 20 mm, 5 μm) (Waters) and separated
on a BEH130 C18 (100 μm × 100 mm, 1.7 μm) (Waters)
at a flow rate of 1 μL/min over a 60 min. gradient (2%
acetonitrile (ACN) 0.1% formic acid (FA) to 30% ACN,
0.1% FA over 40 min; 30-98% ACN, 0.1% FA over 10 min;
98% ACN, 0.1% FA for 5 min; reequilibrate 2% ACN,
0.1% FA). Peptides were detected by a QTRAP® 5500
(AB SCIEX, Framingham, MA) equipped with an Advance
Captivespray™ source (Michrom Bioresources, Inc. Auburn,
CA). Scheduled MRM methods were prepared using
Skyline v1.3 [78] and imported into Analyst 1.5.2
(ABSCIEX). The QTRAP® 5500 was operated in positive
ion mode using scheduled MRM. Result files were
processed and quantitated using Multiquant™ v2.1 with
Scheduled MRM™ algorithm (AB SCIEX), and the results
exported for further statistical analysis. Calibration curves
were generated using a mixture of light and heavy AQUA
peptides spiked into artificial CSF (10 μg/mL bovine albu-
min digest prepared in the same manner as CSF samples).
NrCAM and Chromogranin A enzyme-linked
immunosorbent assays (ELISAs)
CSF samples were analyzed using commercially available
ELISAs for NrCAM (R&D Systems, Inc., Minneapolis,MN) and Chromogranin A (ALPCO Diagnostics, Salem,
NH). The assays were performed according to the man-
ufacturers’ instructions. CSF samples were assayed in
duplicate and had undergone one previous freeze-thaw
cycle after receipt from vendor. For the NrCAM ELISA,
CSF samples were diluted 1/64 in Reagent Diluent
(Catalog # DY995 R&D Systems) and 100 μL of the
diluted samples and kit standards were added per well.
Absorbance was measured at 450 nm with wavelength
correction at 570 nm on a VersaMax plate reader
(Molecular Devices, Sunnyvale, CA). For the Chromogranin
A ELISA, CSF samples were diluted 1/4 in CgA Assay
Buffer (ALPCO Diagnostics) and 25 μL of the diluted sam-
ples and kit standards and controls were added per well.
Absorbance was measured at 450 nm with wavelength
correction at 595 nm on aVersaMax plate reader.
Statistical analysis
Results were imported into TIBCO® Spotfire® 4.0.2
(TIBCO® Software Inc, Somerville, MA) and R statistical
computing and graphics software. Analyses included data
QC for peptide performance (coefficient of variance),
QC of sample preparation (equine myoglobin), group
comparisons (linear regression, (p-values corrected by the
Benjamini & Hochberg method)), longitudinal analysis,
and correlation analysis (Pearson and Spearman).
Measured “values” were transformed using a log base
10 transformation. Annualized rates of change of “values”
were estimated via a linear mixed-effects model [64]
implemented with the ‘nlme’ package in R [79] using
“patients” as random effect. In both the baseline group
comparison model and the longitudinal analysis for
annualized rate of change, we adjusted for age as a continu-
ous covariate, sex, and interactions between age and sex.
Additional files
Additional file 1: Table S1. Selected peptides for CSF AD biomarker
candidates, peptide performance and biological protein function. Table S2.
CSF total protein and Aβ42 do not correlate with chromogranin (CMGA),
neuronal pentraxin receptor (NPTXR) or NrCAM, but tau and p-tau181 do
(Spearman rank correlations in AD patients at baseline).
Additional file 2: Figure S1. The majority of peptides are stable after
one or two freeze-thaw cycles. Log of the mean ratio (light to heavy peptide
pair) observed for 42 peptides between 1 or two freeze thaw cycles in CSF
from three AD patients (shape and color by patient).
Additional file 3: Figure S2. Comparison of levels of detectable peptide
biomarkers with inter-assay CVs of <20% in aged (>60y) cognitively-normal
controls (n = 10), MCI (n = 5), and AD (n = 45) individuals. Differences between
control and AD that reached significance are indicated with an asterisk
(*p = 0.01-0.05, **p = 0.001-0.01, ***p < 0.001, linear regression comparison
of log values corrected by the Benjamini & Hochberg method)
(Control, green-circle, MCI blue-square, AD red-triangle).
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